Showing 5491-5500 of 8888 results for "".
- Cellulite Market Expected to Growhttps://practicaldermatology.com/news/cellulite-market-expected-to-grow/2457792/The cellulite treatment market is expected to grow worldwide, as the obesity epidemic grows. Findings are in the comprehensive research report by Future Market Insights entitled “Cellulite Treatment Market
- Saudi Arabia Welcomes Scalisi Skin Carehttps://practicaldermatology.com/news/saudi-arabia-welcomes-scalisi-skin-care/2457799/Select doctors’ offices and medical clinics across Saudi Arabia now carry the Scalisi collection. This adds to their existing distribution in spas and medispas in the US, Wynn and Encore Resorts in both Las Vegas, and Macau, China, and online on QVC.com, Amazon.com, and
- Study: Derms More Likely than PAs to Catch Early Skin Cancerhttps://practicaldermatology.com/news/study-derms-more-likely-than-pas-to-catch-early-skin-cancer/2457800/Physician assistants may be more likely than dermatologists to perform unnecessary skin biopsies to check for cancer and are less likely to accurately diagnose early stage skin cancers, according to new research conducted by the University of Pittsbur
- Cutera: 20 Years, 20 Productshttps://practicaldermatology.com/news/cutera-20-years-20-products/2457802/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20
- Most Indoor Tanners Aren't Getting Screened for Skin Cancerhttps://practicaldermatology.com/news/most-indoor-tanners-arent-getting-screened-for-skin-cancer/2457801/Most indoor tanners are not getting checked for skin cancer, a new study shows. Researchers analyzed data from the National Health Interview Survey of more than 30,000 U.S. adults. They looked at rates of s
- News You Can Use: Simple One-Page Tool Improves Patient Satisfaction with Doctor Visithttps://practicaldermatology.com/news/news-you-can-use-simple-one-page-tool-improves-patient-satisfaction-with-doctor-visit/2457805/A simple, one-page form given to patients ahead of time can significantly improve satisfaction with care, according to a study by Duke Health researchers. The low-tech tool, which asks for a list of the topics patients wants to discuss during their visit, helps patients focus on what&rsqu
- Using Anti-PD-1 Therapy Pre-Surgery in Melanoma Patients Can Identify Those Most Likely to Benefithttps://practicaldermatology.com/news/using-anti-pd-1-therapy-pre-surgery-in-melanoma-patients-can-identify-those-most-likely-to-benefit/2457806/Shifting use of anti-PD-1 drugs to before surgery may provide clues about which patients will benefit and which may be at increased risk for recurrence, according to new research out of the Abramson Cancer Center of the University of Pennsylvania.
- RealSelf Names Tanja Omeze Chief Marketing Officerhttps://practicaldermatology.com/news/realself-names-tanja-omeze-chief-marketing-officer/2457808/Ms. Tanja Omeze is RealSelf’s first ever chief marketing officer (CMO). As CMO, Ms. Omeze leads global marketing to increase awareness, engagement and connections among and between consumers and medical aesthetic professionals. Ms. Omez
- Take That, Kim and Kylie : Most Millennials Don't Want Your Advice on Cosmetic Surgeryhttps://practicaldermatology.com/news/take-that-kim-and-kylie/2457812/When it comes to deciding on nips and tucks, millennials are not inclined to trust social media or celebs, a new
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename E